P2, N=90, Not yet recruiting, SWOG Cancer Research Network

P2/3, N=960, Not yet recruiting, Merck Sharp & Dohme LLC

Vignettes explored access to evidence-informed but not universally funded therapies: blinatumomab for low-risk relapse of B-cell acute lymphoblastic leukemia (B-ALL), larotrectinib for TRK-fused soft tissue sarcoma, PBT for unresectable head-and-neck sarcoma, and tisagenlecleucel for first relapse of B-ALL in a patient with Down syndrome. Access to evidence-informed cancer therapies for Canadian children remains variable. Universal funding, simplified approval processes, and the establishment of Canadian PBT centres to reduce travel burden, would ensure timely, equitable access to high-cost therapies.

P1, N=70, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting

P2/3, N=340, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Oct 2029 --> Oct 2033 | Trial primary completion date: Feb 2029 --> Oct 2033

P2, N=71, Active, not recruiting, The Lymphoma Academic Research Organisation | Trial completion date: Dec 2026 --> Jun 2027

T-cell engager therapies, including bispecific T-cell engagers and the immune-mobilizing monoclonal T-cell receptor against cancer tebentafusp, are an emerging class of anticancer immunotherapy, with rapid expansion of the class since initial approval of blinatumomab in 2014 and with distinct dermatologic adverse events increasingly recognized across agents. Tebentafusp and talquetamab demonstrate highest rates of notable dermatologic toxicity reflecting on-target off-tumor cutaneous effects...Across agents, most dermatologic adverse events can be managed with topical corticosteroids, emollients, antihistamines, or brief courses of systemic corticosteroids without requiring treatment discontinuation. Recognition of these agent-specific and mechanistically linked patterns is essential for dermatologists as T-cell engager therapies become increasingly integrated into oncology practice.

P2, N=25, Active, not recruiting, The First Affiliated Hospital of Soochow University

P3, N=420, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting | Trial completion date: Aug 2033 --> Apr 2032 | Trial primary completion date: Nov 2032 --> Aug 2031

P1/2, N=58, Not yet recruiting, Merck Sharp & Dohme LLC

P1, N=54, Recruiting, Novartis Pharmaceuticals | Trial completion date: Jul 2027 --> Nov 2027 | Trial primary completion date: Jul 2027 --> Nov 2027

P1, N=30, Recruiting, AbbVie | Not yet recruiting --> Recruiting